# An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years

> **NCT01480674** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 160 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT01480674
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-28
- **Primary completion:** 2012-11-16
- **Final completion:** 2012-11-16
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2017-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01480674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01480674, "An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01480674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*